Michael Dube is an Infectious Disease physician. ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1520 San Pablo St Ste 1000
Los Angeles, CA 900335312
Telephone
323-442-5100Provider last certified this registry record 8 May 2024.
Clinical trials
- Rice Bran Supplementation in Treated HIV Infection
Sponsor: University of Southern California
- Sitagliptin for Reducing Inflammation and Immune Activation
Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Effect of Vitamin D Supplementation on Bone Turnover Markers During PrEP in MSM
Sponsor: University of California, San Diego
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20251 payment
- Merck Sharp & Dohme LLCProgram year20252 payments
- BioFire Diagnostics, LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
53.6%Statin53.6%Rosuvastatin Calcium100%Part D<11 patientsGenitourinary & hormones
46.4%alpha-Adrenergic Blocker46.4%Tamsulosin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 1998–2020 per NIH RePORTER. The latest:
- Phase II trial of tesamorelin for cognition in aging HIV-infected persons
University of California, San Diego
FY2020$741,150R01AG048650 - Phase II trial of tesamorelin for cognition in aging HIV-infected persons
University of California, San Diego
FY2019$646,035R01AG048650 - Microbial Translocation and HIV-Related Endothelial Dysfunction
University of Southern California
FY2010$243,000R21AI091492
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”